“Other AI technologies simply do not deliver the level of performance, speed and accuracy that ProFound AI offers,” according to Meghan Musser, DO, Radiologist, Kettering Health. Built with the latest in deep-learning technology, it provides radiologists with crucial information, such as Certainty of Finding and Case Scores, which are relative scores that represent the algorithm’s confidence that a detection or case is malignant.
ProFound AI rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities with unrivaled accuracy.
It has helped make our breast screening program one of the best – not only in the state, but also the world.” I believe that patients without access to ProFound AI are at a disservice. It is light years ahead of other technologies, which simply cannot measure up. A game-changing technology, ProFound AI has empowered us to offer world-class, personalized patient care.
“We looked at other AI technologies, but have ultimately found them to be like smoke and mirrors compared to ProFound AI. “We recently updated our breast screening technology at our facility, and ProFound AI is the icing on the cake,” said Sally Grady, Director, Kettering Breast Evaluation Centers, Kettering Health. ProFound AI for DBT offers clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, while also improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent. ProFound AI is a high-performance, deep-learning workflow solution trained to detect malignant soft-tissue densities and calcifications.
The event, which will be moderated by Michael Klein, Chairman and CEO of iCAD, Inc., Stacey Stevens, President of iCAD, Inc., and Jeffrey Sirek, Chief Commercial Officer of iCAD, Inc., will feature a roundtable discussion on iCAD’s Breast Health Solutions, including ProFound ® AI, the world’s first artificial intelligence (AI) software application trained using deep-learning technology on digital breast tomosynthesis (DBT) images to be FDA cleared.
Smith, MD, Dermatologist, Chief Executive Officer, Georgia Skin and Cancer Clinic